CRL Charles River Laboratories

$161.66

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Charles River Laboratories

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Website: https://www.criver.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1100682
Address
251 BALLARDVALE ST, WILMINGTON, MA, US
Valuation
Market Cap
$5.21B
P/E Ratio
530.25
PEG Ratio
3.40
Price to Book
1.50
Performance
EPS
$0.20
Dividend Yield
—
Profit Margin
0.55%
ROE
0.71%
Technicals
50D MA
$153.54
200D MA
$185.39
52W High
$254.15
52W Low
$91.86
Fundamentals
Shares Outstanding
49M
Target Price
$159.11
Beta
1.45

CRL EPS Estimates vs Actual

● Estimated
● Actual

CRL News & Sentiment

Aug 11, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Interpreting Charles River ( CRL ) International Revenue Trends
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Aug 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Charles River ( CRL ) Q2 EPS Jumps 11%
Charles River Laboratories International ( NYSE:CRL ) , a global provider of laboratory services and research models for drug development, announced its latest earnings results on August 6, 2025. The company reported GAAP revenue of $1,032.1 million, slightly up 0.6% year-over-year ( GAAP ) , and ...
Aug 06, 2025 • Benzinga SOMEWHAT-BULLISH
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Charles River ( NYSE:CRL )
Q2 adjusted EPS of $3.12 beat estimates of $2.50, rising 11.4% year over year. FY25 EPS outlook raised to $9.90-$10.30 vs. prior guidance of $9.30-$9.80 The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. Charles River Laboratories ...
Aug 06, 2025 • Zacks Commentary NEUTRAL
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Aug 06, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Charles River Laboratories ( CRL ) Q2 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Organon ( OGN ) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.082
50 articles with scored sentiment

Overall Sentiment:

Neutral

CRL Reported Earnings

Feb 12, 2025
Dec 31, 2024 (Pre market)
0.13 Surprise
  • Reported EPS: $2.66
  • Estimate: $2.53
  • Whisper: —
  • Surprise %: 5.2%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.16 Surprise
  • Reported EPS: $2.59
  • Estimate: $2.43
  • Whisper: —
  • Surprise %: 6.6%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.41 Surprise
  • Reported EPS: $2.80
  • Estimate: $2.39
  • Whisper: —
  • Surprise %: 17.1%
May 09, 2024
Mar 31, 2024 (Pre market)
0.2 Surprise
  • Reported EPS: $2.27
  • Estimate: $2.07
  • Whisper: —
  • Surprise %: 9.7%
Feb 14, 2024
Dec 31, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $2.46
  • Estimate: $2.40
  • Whisper: —
  • Surprise %: 2.5%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.35 Surprise
  • Reported EPS: $2.72
  • Estimate: $2.37
  • Whisper: —
  • Surprise %: 14.8%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $2.69
  • Estimate: $2.64
  • Whisper: —
  • Surprise %: 1.9%
May 11, 2023
Mar 31, 2023 (Pre market)
0.19 Surprise
  • Reported EPS: $2.78
  • Estimate: $2.59
  • Whisper: —
  • Surprise %: 7.3%
Feb 22, 2023
Dec 31, 2022 (Pre market)
0.23 Surprise
  • Reported EPS: $2.98
  • Estimate: $2.75
  • Whisper: —
  • Surprise %: 8.4%

Financials